TY - JOUR
T1 - 5α-reduced progesterone metabolites are essential in hamster VTA for sexual receptivity
AU - Frye, Cheryl A.
AU - Leadbetter, Elizabeth A.
N1 - Funding Information:
Acknowledgements This research was supported by a Roger C. Schmutz Faculty Research Grant to CAF, and Sigma Xi and Mellon Foundation Grants-in-Aid of Research to EAL, as well as the Biology and Psychology Departments at Bates College. We thank Merck, Sharpe, and Dohme (Rahway, N.J.) for the gift of 4MA and Drs. Mary Erskine, Harry Karavolas and Sheryl Smith for advice about the use of 4MA. Helpful comments were provided by Drs. Diane Cowan, Joseph DeBold, Paul Doherty, Cheryl McCormick and Eli Minkoff. These data were presented in part at the 1993 Conference on Reproductive Behavior (East Lansing, Michigan) and the 1993 Society for Neuroscience Meeting (Washington, DC).
PY - 1994
Y1 - 1994
N2 - Progesterone's (P) actions in the ventral medial hypothalamus (VMH) and the ventral tegmental area (VTA) are essential for sexual receptivity in hamsters. This study investigates the notion that P works in the VTA in the absence of intracellular P receptors (PRs) by 5α-reduction to progestins, which would subsequently bind to membrane γ-Aminobutyric Acid receptor complexes (GBRs). To test the importance of P metabolism, a 5α-reductase inhibitor, 17β-N, N-diethylcarbamoyl-4-methyl-4aza-5α-androstan-3-one (4MA) was administered SC (0, 3, 9, 15, 24, or 30mg/kg) to ovx estradiol benzoate(EB)-primed hamsters, followed by one of six doses of SC P (0, 25, 50, 100, 200, or 500μg) and sexual receptivity testing. 200μg P-treated animals administered higher (24 and 30 mg/kg) doses of 4MA had significantly decreased total lordosis durations (TLDs) compared to 0 mg/kg 4MA controls (exp 1). In exp 2, 4MA was aimed bilaterally at the VTA prior to SC P. After 200μg P, animals had significantly lower TLDs than after 500μg P, 3 hours following bilateral VTA implantation of 4MA, but not cholesterol. In exp 3, cycling female hamsters were infused with 1.0μg 4MA or vehicle unilaterally into the VTA on diestrus, proestrus, and estrus. 4MA, but not vehicle, infusions into the VTA interrupted receptivity in estrus and proestrus animals, but had no effect on diestrus animals. 4MA's reduction of receptivity when given systematically and intracranially strongly supports the hypothesis that 5α-reduced P metabolites, possibly interacting with GBRs in the VTA, are essential for sexual receptivity in hamsters.
AB - Progesterone's (P) actions in the ventral medial hypothalamus (VMH) and the ventral tegmental area (VTA) are essential for sexual receptivity in hamsters. This study investigates the notion that P works in the VTA in the absence of intracellular P receptors (PRs) by 5α-reduction to progestins, which would subsequently bind to membrane γ-Aminobutyric Acid receptor complexes (GBRs). To test the importance of P metabolism, a 5α-reductase inhibitor, 17β-N, N-diethylcarbamoyl-4-methyl-4aza-5α-androstan-3-one (4MA) was administered SC (0, 3, 9, 15, 24, or 30mg/kg) to ovx estradiol benzoate(EB)-primed hamsters, followed by one of six doses of SC P (0, 25, 50, 100, 200, or 500μg) and sexual receptivity testing. 200μg P-treated animals administered higher (24 and 30 mg/kg) doses of 4MA had significantly decreased total lordosis durations (TLDs) compared to 0 mg/kg 4MA controls (exp 1). In exp 2, 4MA was aimed bilaterally at the VTA prior to SC P. After 200μg P, animals had significantly lower TLDs than after 500μg P, 3 hours following bilateral VTA implantation of 4MA, but not cholesterol. In exp 3, cycling female hamsters were infused with 1.0μg 4MA or vehicle unilaterally into the VTA on diestrus, proestrus, and estrus. 4MA, but not vehicle, infusions into the VTA interrupted receptivity in estrus and proestrus animals, but had no effect on diestrus animals. 4MA's reduction of receptivity when given systematically and intracranially strongly supports the hypothesis that 5α-reduced P metabolites, possibly interacting with GBRs in the VTA, are essential for sexual receptivity in hamsters.
UR - http://www.scopus.com/inward/record.url?scp=0028180389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028180389&partnerID=8YFLogxK
U2 - 10.1016/0024-3205(94)00548-6
DO - 10.1016/0024-3205(94)00548-6
M3 - Article
C2 - 8107510
AN - SCOPUS:0028180389
SN - 0024-3205
VL - 54
SP - 653
EP - 659
JO - Life Sciences
JF - Life Sciences
IS - 10
ER -